Hematological Malignancies Clinical Trial
— HemaTMAOfficial title:
Tissue Microarray of Hematological Malignancies: Search for Novel Regulators of Disease Pathology Across Disease Entities
Verified date | April 2024 |
Source | Tampere University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The aim of the study is to create new tools for improving management of patients with hematological malignancies by combining extensive clinical data from patients newly diagnosed with hematological malignancies and innovative laboratory analyses made on available tissue samples in regional biobanks from these patients.
Status | Active, not recruiting |
Enrollment | 5000 |
Est. completion date | December 31, 2026 |
Est. primary completion date | December 31, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - hematological malignancy/neoplasm Exclusion Criteria: - Non-sufficient data available |
Country | Name | City | State |
---|---|---|---|
Finland | Tampere Univerisity Hospital | Tampere |
Lead Sponsor | Collaborator |
---|---|
Tampere University Hospital | Fimlab Oy, Helsinki University Central Hospital, Tampere University, University of Eastern Finland |
Finland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-free survival (PFS) | Time from the first line treatment for hematological malignancy until the date of first documented relapse or transformation or death of any cause, whichever came first, assessed up to the end of the study period (April 2019). | From the first line treatment up to the end of the study period (April 2019). | |
Primary | Overall survival (OS) | Survival time from the diagnosis of hematological malignancy until the date of death of any cause, assessed up to the end of the study period (April 2019). | From the diagnosis up to the end of the study period (April 2019). | |
Primary | Response to treatment | Best response to the first line treatment for the hematological malignancy, according to malignancy in question, e.g. complete response (CR), stringent complete response (sCR), partial response (PR), very good partial response (VGPR), stable disease (SD), progressive disease (PD), treatment failure, clinical response, hematological response etc. | From the first line treatment up to the end of the study period (April 2019). | |
Primary | Event-free survival (EFS) | Survival time from the first line treatment for hematological malignancy until any primary event (death, relapse, disease progression/transformation, secondary malignancy, resistant disease etc.), whichever came first, assessed up to the end of the study period (April 2019). | From the first line treatment up to the end of the study period (April 2019). | |
Secondary | Sepsis or other life-threatening infection | Fulminant infection after diagnosis | From the first line treatment up to the end of the study period (April 2019). | |
Secondary | Multiple organ failure | Altered organ function in acutely ill patient | From the first line treatment up to the end of the study period (April 2019). | |
Secondary | Thrombo-embolism | Venous thromboembolism | From the first line treatment up to the end of the study period (April 2019). | |
Secondary | Disease transformation | Hematological malignancy transforms into another malignancy | From the diagnosis up to the end of the study period (April 2019). | |
Secondary | ICU admission | Admission to intensive care unit | From the first line treatment up to the end of the study period (April 2019). | |
Secondary | Adverse effects | Treatment-related adverse effects/events | From the first line treatment up to the end of the study period (April 2019). | |
Secondary | Secondary malignancy | Secondary malignancy after the diagnosis of hematological malignancy | From the first line treatment up to the end of the study period (April 2019). | |
Secondary | Relapse | Relapse after or during the treatment. | From the first line treatment up to the end of the study period (April 2019). | |
Secondary | Complete remission | Complete remission after the treatment | From the first line treatment up to the end of the study period (April 2019). | |
Secondary | Time to complete remission | Time to complete remission | From the first line treatment up to the end of the study period (April 2019). | |
Secondary | Best response | Best response e.g. hematological remission, molecular remission, radiological remission | From the first line treatment up to the end of the study period (April 2019). | |
Secondary | Time to best response | Time to best response e.g. hematological remission, molecular remission, radiological remission | From the first line treatment up to the end of the study period (April 2019). |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03248479 -
Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies
|
Phase 1 | |
Recruiting |
NCT05454241 -
CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies
|
Phase 2 | |
Recruiting |
NCT06041815 -
Correlation Between Gut Microbiota and Clinical Response to CAR-T Treatment for Hematological Malignancies
|
||
Active, not recruiting |
NCT05005442 -
A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)
|
Phase 2 | |
Recruiting |
NCT02300571 -
Observational Study of the Combination of Post-transplant High Dose Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-versus-Host Disease in Patients Eligible to Allogeneic Hematopoietic Stem Cell Transplant
|
N/A | |
Active, not recruiting |
NCT01428973 -
Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens
|
Phase 2 | |
Completed |
NCT01162096 -
Reduced Intensity Haploidentical Transplant for Hematological Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT00379587 -
Rituximab for Prevention of Chronic GVHD
|
Phase 1/Phase 2 | |
Terminated |
NCT00506948 -
Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)
|
Phase 2 | |
Active, not recruiting |
NCT04557098 -
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
|
Phase 2 | |
Recruiting |
NCT04283097 -
Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects
|
Phase 1 | |
Completed |
NCT03067155 -
CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation.
|
Phase 2 | |
Completed |
NCT01725555 -
A Study to Assess the Effect of Food on the Bioavailability of the IGF-1R Inhibitor AXL1717 in Patients With Advanced Malignant Tumors
|
Phase 1 | |
Completed |
NCT00438178 -
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies
|
Phase 1 | |
Completed |
NCT03711604 -
Compassionate Use Study of Tenalisib (RP6530)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT01168882 -
Safety and Tolerability of RGB-286638 in Patients With Selected, Relapsed or Refractory Hematological Malignancies
|
Phase 1 | |
Completed |
NCT01246206 -
Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT
|
Phase 2 | |
Completed |
NCT01172132 -
The Use of Intensive Care in Critically Ill Cancer Haematological Patients: "TRIAL-OH"
|
N/A | |
Completed |
NCT00506402 -
A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT00163644 -
RCT to Investigate Whether an Exercise Programme Improves the Physical Performance and QOL After BMT
|
N/A |